Gabapentin overdose and abuse

Gabapentin overdose and abuse Reactions 1680, p148 - 2 Dec 2017 O S Hyponatraemia: case report A 51-year-old man developed hyponatraemia following gabapentin overdose, additionally he was also abusing gabapentin prescribed for restless leg syndrome (off label use) [route and time to reaction onset not stated]. The man was transferred to the behavioural care pavilion for depression and anxiety. Before presentation, he was admitted to ICU for gabapentin overdose (78g) over past 48 hours. He was treated for hyponatraemia associated with gabapentin overdose, which he was prescribed for restless leg syndrome. Records provided by transferring facility stated that he had been to hospital 32 times in past 8 months and had 10 hospitalisations, out of which eight were related to overdose both intentional and unintentional. Prior to admission he was treated with various medications including gabapentin. He denied current use or abuse of opiods, alcohol or benzodiazepine, but urine drug screen was positive for opioids. It was discovered that in last several months, three different doctors had prescribed gabapentin to him and he transferred prescriptions between various pharmacies. He also had a history of seizures related to overdose and withdrawal of gabapentin. Prior to presentation to emergency department, he reported of seizure activity and vomiting. During inpatient treatment, he denied for cravings for any substance including gabapentin, except tobacco. During hospitalisation, the man was treated for anxiety and depression and was discharged after 6 days. Additionally, his psychiatric medications were adjusted and he was started on naltrexone. Gabapentin treatment was stopped and for restless leg syndrome, he was started on ropinirole. Author comment: "The patient was treated for hyponatremia related to gabapentin overdose prior to transfer." "The following case reports a patient with compulsive gabapentin abuse". Banker K, et al. Compulsive gabapentin abuse despite lack of desirable effects: A case report. Journal of Substance Use 22: 661-663, No. 6, 2 Nov 2017. Available from: URL: - USA 803285187 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals

Gabapentin overdose and abuse

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial